Last reviewed · How we verify

NCT05078281: Asthma

Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Status unknown Last updated 16 November 2021
What this trial tests

trial in Asthma; Eosinophilic in 60 participants. Status unknown.

Timeline
1 November 2020
Primary endpoint
1 April 2022
1 April 2022

Quick facts

Lead sponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date1 November 2020
Primary completion1 April 2022
Estimated completion1 April 2022
Sites1 location across Spain

Conditions studied

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full company profile →

Who can join

18 and older, any sex, with Asthma; Eosinophilic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective, multicenter, routine clinical practice study with consecutive inclusion of adult patients with severe eosinophilic asthma receiving benralizumab treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons.
    Hussain M, Liu G. · · 2024 · cited 60× · PMID 38474348 · DOI 10.3390/cells13050384

Verify or expand the search:

Other recruiting trials for Asthma; Eosinophilic

Currently open trials in the same condition.

Other Fundación Pública Andaluza para la gestión de la Investigación en Sevilla trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05078281.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing